Sign In
Buy ABEO
$6.42
-0.0500 (-0.773%)
At Close: Jul 31, 2026
Abeona Therapeutics Inc. (ABEO) CEO Michael Amoroso on Q4 2020 Results - Earnings Call Transcript
02:34pm, Thursday, 25'th Mar 2021
Abeona Therapeutics Inc. (ABEO) CEO Michael Amoroso on Q4 2020 Results - Earnings Call Transcript
Abeona Therapeutics Announces Appointment of Two New Independent Members to its Board of Directors
07:30am, Thursday, 25'th Mar 2021
Refreshed board to bring fresh perspectives, relevant expertise and diverse experience Refreshed board to bring fresh perspectives, relevant expertise and diverse experience
Abeona Therapeutics (ABEO) Reports Q4 Loss, Lags Revenue Estimates
06:17pm, Wednesday, 24'th Mar 2021
Abeona Therapeutics (ABEO) delivered earnings and revenue surprises of -88.89% and -45.95%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stoc
Abeona Therapeutics Announces 2020 Financial Results and Recent Operational Progress
04:01pm, Wednesday, 24'th Mar 2021
Fourth patient treated in pivotal Phase 3 VIITAL™ study of EB-101 in RDEB after successful Type B meeting with FDA
NEW YORK, March 23, 2021 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary dut
Week 9 MDA Breakout Stocks - March 2021: Short-Term Picks To Give You An Edge
07:20am, Sunday, 28'th Feb 2021
Week 9 MDA Breakout Stocks - March 2021: Short-Term Picks To Give You An Edge
Abeona Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference
07:30am, Monday, 22'nd Feb 2021
NEW YORK and CLEVELAND, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that the company will present at
In addition to preservation of neurocognitive development with ABO-102 in MPS IIIA, new clinical results of ABO-102 in MPS IIIA and ABO-101 in MPS IIIB continue to show dose-dependent and sustained re
NEW YORK and CLEVELAND, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that it will host a live webinar
Clinical trial amendment successfully completed for co-primary endpoints of partial wound closure and mean pain reduction Clinical trial amendment successfully completed for co-primary endpoints of
Do Options Traders Know Something About Abeona (ABEO) Stock We Don't?
09:47am, Tuesday, 12'th Jan 2021
Investors need to pay close attention to Abeona (ABEO) stock based on the movements in the options market lately.
NEW YORK and CLEVELAND, Dec. 21, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that abstracts detailing new inte
Why This Abeona Therapeutics Analyst Is Turning Bullish After Q3 Print
11:24am, Wednesday, 11'th Nov 2020
Abeona Therapeutics Inc's (NASDAQ: ABEO) stock does not reflect the company's in-house manufacturing capabilities and pipeline, according to Cantor Fitzgerald. The Abeona Therapeutics Analyst: Kriste
Abeona Therapeutics Reports Third Quarter Financial Results
04:05pm, Monday, 09'th Nov 2020
Conference call scheduled for Tuesday, November 10, 2020 at 8:30 a.m. ET Conference call scheduled for Tuesday, November 10, 2020 at 8:30 a.m. ET
Abeona Therapeutics Announces the Appointment of Michael Amoroso as Chief Operating Officer
06:30am, Tuesday, 27'th Oct 2020
NEW YORK and CLEVELAND, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that Michael Amoroso, Senior Vice
